Private Health Insurance in France: Between Europeanization and Collectivization

Abstract

Private health insurance (PHI) in France has been facing critical changes over the past 30 years. A complementary and voluntary scheme, it has been historically dominated by nonprofit entities. However, the share of for‐profit insurance companies in the sector has significantly increased. Nonprofit firms also changed their strategies and mimicked some for‐profit behaviors. The present paper argues that this process is a result of the conflict‐provoking coevolution of the insurance and health care sectors. Trying to improve the regulation of the insurance industry as whole, two European directives first jeopardized the business model of nonprofit entities. Then, two national reforms designed to improve health coverage significantly increased competition among insurers, notably in the area of corporate‐level contracts. Decoupling the insurance and health care sectors has become a major source of policy feedback and unexpected outcomes of reforms affecting the very organization of PHI. Context In France, private health insurance (PHI) has an exceptionally high level of coverage and accounts for 13.7% of health expenditures. A complementary and voluntary scheme, it has been historically dominated by nonprofit, mutual benefit societies. Over the past 20 years, however, the market share of for‐profit insurance companies has increased by 47%. Financialization of the field developed, and competition based on new risk management strategies also increased. The broad aim of this paper is to characterize and to elucidate the causes of this trend. More specifically, we are interested in how and to what extent a series of supranational and national policies contributed to this situation. Method Our data come from three sources. We first reviewed documents published by health insurers, government reports, and newspaper articles. We then conducted two semistructured interview campaigns between September 2017 and May 2018. The first mostly covered private and public actors and their involvement in European Union (EU) policymaking (n = 21). The second series of interviews was conducted with another group of actors directly involved at the French level (n = 16). Findings Our findings support preliminary observations. PHI in France, we argue, is indeed facing a development of competition and marketlike instruments. Four major policies (two EU directives and two national reforms) played a significant role in this outcome. Surprisingly, however, it has never been the purpose of legislators and policymakers: while EU directives created a regulatory framework for insurance activities within the Single Market, policies adopted at the national level initially aimed at improving health coverage. We show that it is the interactions and the noncoordination among all of these policies that explain their unexpected outcome. Conclusions The trend described in this paper is twofold. The first is Europeanization, as PHI in France is increasingly affected by EU legislation. Since this framework tends to favor larger firms and for‐profit companie...

COVID-19 Medical and Pharmacological Management in the European Countries Compared to Italy: An Overview

“…These organizations, depending on the proposed contract, reimburse what the state does not reimburse. Therefore, in France, wide cooperation between public and private health management is orchestrated by the “mutuelles” [ 68 ].…”

The (mis)fit of policy programs to political institutions and its influence on programmatic action – How crisis has differently hit French and German health policy

“…However, policies adopted after 2010 still followed the policy program promoted by the programmatic group. Although the reforms made use of new public management tools, the general tendency towards a re‐centralization of competences remained (Simonet, 2017), even though there are some recent tendencies of marketization of the private health insurance, though unintended (BenoÎt & Coron, 2019). The regulatory mechanisms remain consistent with the political system in France, and the consistency of objectives and instruments is ensured as the measures taken still aim at increasing efficiency in health care spending, being oriented towards prevention and digitalization, and strengthening the state (Lombrail, 2015).…”

Development of regional market of corporate voluntary health insurance: The case of St. Petersburg

“…Система здравоохранения и доступность медицинской помощи Финансовые инвестиции государства в здравоохранение [Tynkkynen et al, 2018] Государственное регулирование, в том числе предоставление налоговых льгот для работников и работодателей [Gross, Brammli-Greenberg, 2004;King, Mossialos, 2005;Alexandersen et al, 2016;Benoît, Coron, 2019] Обеспеченность врачами и стационарами [Хохлова, Шатонов, 2013;Шатонов, 2015;Foubister et al, 2006;Khokhlova et al, 2015;Meleddu, Pulina, Scuderi, 2020] Медицинская инфляция [Лукьянова, 2019] Удовлетворенность индивидов государственным здравоохранением [Jowett, 2002;Tynkkynen et al, 2018;Meleddu, Pulina, Scuderi, 2020] Информированность граждан об условиях страхования [Kaplan, Shahar, Tal, 2017] Социальные Личностные характеристики застрахованных Доход, квалификация, образование, возраст, пол, здоровье, вредные привычки, семейное положение [Селезнева, 2016;Аистов, Александрова, 2018;Jowett, 2002;King, Mossialos, 2005;Foubister et al, 2006;Mathur et al, 2015] Окончание табл. 1 Н. П. Дроздова, О. А. Марычева, Т. М. Скляр В исследовании рынка ДМС Москвы, проведенном в 2018 г. страховой компанией «АСТ Компания», увеличение спроса в сырьевых отраслях и отраслях «новой экономики» выделено среди факторов, влияющих на темпы роста премий по ДМС.…”

“…В работе [Benoît, Coron, 2019] показано, что усиление государственного регулирования дополнительного ДМС ведет к стандартизации страховых программ и уменьшает свободу выбора для страхователей, т. е. может препятствовать развитию рынка ДМС. Доступность медицинской помощи, измеряемая числом врачей на 10 тыс.…”